Van beleggers
voor beleggers
desktop iconMarkt Monitor

Ontvang nu dagelijks onze kooptips!

word abonnee

Bayer Jaardraadje 2024

304 Posts
Pagina: «« 1 ... 11 12 13 14 15 16 »» | Laatste | Omlaag ↓
  1. forum rang 7 4finance 15 april 2024 12:49
    BAYER, weer niet zo'n fijn bericht....

    LONDON, April 12 (Reuters) - Bayer's patent covering its best-selling blood thinner Xarelto is invalid, London's High Court ruled on Friday in a blow to the German drugmaker.
    The company's blockbuster Xarelto drug generated nearly $4.1 billion in revenue in 2023, according to research firm Statista.
    Bayer's attempts to replace Xarelto were thrown into doubt last year when it aborted a large late-stage trial testing a new anti-clotting drug due to lack of efficacy.
    Its European patent over once-daily rivaroxaban, with a brand name of Xarelto, has now been declared invalid following legal challenges brought by Sandoz and other rival manufacturers.
    Judge Richard Hacon said Bayer's patent was invalid because of the lack of an "inventive step" in developing the drug.
    Friday's decision paves the way for other drug makers to launch generic versions of rivaroxaban, though Bayer said it would be seeking to block such attempts pending any appeal.
    "We are seeking permission to appeal this decision and seeking interim injunctive relief to prevent the launch of 10mg, 15mg and 20mg generic rivaroxaban products," a Bayer spokesperson said in a statement.
  2. forum rang 7 LL 17 april 2024 18:23
    Stifel lowers its target price

    (CercleFinance.com) - While maintaining its 'hold' recommendation on Bayer shares, Stifel has lowered its TP for them from E42 to E30, which is based on the historical P/E and EV/EBITDA multiples applied to its 2024 projections.

    The broker anticipates adjusted EBITDA of E4bn for Q1 2024, down 11% y-o-y, mainly due to Agrochemicals, but says it is below consensus in each of the German group's three segments.

    Stifel expects the year-on-year trend to improve in H2, with cost savings and easy comparables, but its 2024 EBITDA forecast of E10.1bn is at the low end of the target range.

    Copyright (c) 2024 CercleFinance.com. All rights reserved
  3. forum rang 7 4finance 18 april 2024 16:53
    quote:

    N audio schreef op 18 april 2024 09:38:

    Dezelfde patentstrijd mbt Xarelto is overigens wel recent gewonnen in Nederland, Duitsland en Zweden.
    Sinds afgelopen Woensdag is het wel regelmatig topdrukte geweest bij het uitleenloket voor aandelen.
    Firma list en bedrog druk bezig met het lenen van de stukken.
    BAYER, onder de 20,00 ga ik eens nadenken om misschien wat te kopen.
    Echter de komende 3 jaar zeker geen dividend hier en veel onzekerheid.
    Er zijn mooiere aandelen met (veel) dividend.
    Bij een terugval van de beurzen gaat dit ook weer onderuit.
  4. forum rang 6 N audio 24 april 2024 12:32
    Shortvolume ratio is nu hoog bij Bayer.
    Met andere woorden: shortsellers zijn proactief bezig de koers continue te drukken.
    Blijkbaar is het interessant om de koers actief aan de ketting te leggen?
    Wanneer Bayer dus niet op mag lopen, kan je de vraag stellen waarom dit zo belangrijk is voor shortende partijen?

    Wellicht is het aandeel interessanter dan we vermoeden? Anders probeer je de boel toch niet constant uit te roken, en aan de boom blijven schudden?
    Afgelopen week regelmatig shortvolume ratio van rond de 80%. Bron Fintel.
    Natuurlijk is dat bij één broker, maar ik denk dan toch dat de "heren" dit spelletje elders ook spelen.

    Ik ben toch benieuwd.
  5. forum rang 7 4finance 24 april 2024 13:27
    quote:

    N audio schreef op 24 april 2024 12:32:

    Shortvolume ratio is nu hoog bij Bayer.
    Met andere woorden: shortsellers zijn proactief bezig de koers continue te drukken.
    Blijkbaar is het interessant om de koers actief aan de ketting te leggen?
    Wanneer Bayer dus niet op mag lopen, kan je de vraag stellen waarom dit zo belangrijk is voor shortende partijen?

    Wellicht is het aandeel interessanter dan we vermoeden? Anders probeer je de boel toch niet constant uit te roken, en aan de boom blijven schudden?
    Afgelopen week regelmatig shortvolume ratio van rond de 80%. Bron Fintel.
    Natuurlijk is dat bij één broker, maar ik denk dan toch dat de "heren" dit spelletje elders ook spelen.

    Ik ben toch benieuwd.
    Feit is natuurlijk wel als er ook maar een klein beetje positief nieuws komt. vliegt het aandeel omhoog.
    Dan gaat er flink gecoverd worden in een korte tijd en kan de koers "tijdelijk"fors oplopen.
    In die zin kan je zeggen; BAYER is een buy.
  6. forum rang 6 N audio 24 april 2024 14:04
    quote:

    4finance schreef op 24 april 2024 13:27:

    [...]

    Feit is natuurlijk wel als er ook maar een klein beetje positief nieuws komt. vliegt het aandeel omhoog.
    Dan gaat er flink gecoverd worden in een korte tijd en kan de koers "tijdelijk"fors oplopen.
    In die zin kan je zeggen; BAYER is een buy.
    Ik blijf het maar lastig vinden. Wat andere poster hierboven schreef, ja hij heeft een punt.
    Maar dat is enkel van toepassing wanneer er de komende jaren helemaal niets meer uit de koker van Bayer zou vloeien. En dat vind ik maar moeilijk om aan te nemen.
    Ik heb een overzichtelijke positie hier, die ik enkel ga uitbreiden wanneer dat de moeite zou lonen.
  7. forum rang 7 4finance 24 april 2024 14:13
    quote:

    N audio schreef op 24 april 2024 14:04:

    [...]

    Ik blijf het maar lastig vinden. Wat andere poster hierboven schreef, ja hij heeft een punt.
    Maar dat is enkel van toepassing wanneer er de komende jaren helemaal niets meer uit de koker van Bayer zou vloeien. En dat vind ik maar moeilijk om aan te nemen.
    Ik heb een overzichtelijke positie hier, die ik enkel ga uitbreiden wanneer dat de moeite zou lonen.
    Tja, ik volg het aandeel nog steeds met aandacht, maar op dit niveau ga ik hier geen aandelen kopen.
    Mijn verkochte Bayer positie zit in o.a AMG, Besi en Flow traders.
    AMG heb ik heel laag kunnen kopen en de 2 anderen lopen ook mooi omhoog.
    Op deze posities inmiddels behoorlijk wat winst.
    Het skippen van dividend bij BAYER voor minimaal 3 jaar is iets wat beleggers niet leuk vinden.
  8. forum rang 7 LL 25 april 2024 09:22
    UPDATE 1-Judge slashes $857 mln Monsanto verdict to $438 mln in PCBs case

    By Clark Mindock

    April 24 (Reuters) - A Washington state judge has nearly halved a $857 million verdict against Bayer’s Monsanto in a lawsuit over chemical pollution at a Seattle-area school, ruling that the company should pay $438 million instead.

    Monsanto spinoff Pharmacia was found liable by a jury in December for selling polychlorinated biphenyls (PCBs) used in the Sky Valley Education Center in Monroe, Washington, that were not safe and did not contain adequate warnings.

    The verdict included $73 million in compensatory damages and $784 million in punitive damages for the plaintiffs, seven former students and parent volunteers at the school who said PCBs caused them neurological, endocrine system and other health issues.

    King County Superior Court Judge Jim Rogers let the $73 million component stand in a ruling on Tuesday, but he reduced punitive damages to five times that amount, or $365 million, and shaved another $1.5 million from the judgment to account for a related settlement.

    Monsanto had argued in January that the original award was unconstitutionally excessive. The U.S. Supreme Court has said that punitive damages should generally not be more than nine times compensatory damages.

    A spokesperson for Monsanto, which agreed to defend Pharmacia in PCBs litigation, said in a statement Wednesday that the company is pleased with the decision but plans to appeal the jury's findings. The spokesperson said the award is still too high and that the plaintiffs were not exposed to unsafe levels of PCBs.

    Spokespeople for the plaintiffs declined to comment on Wednesday.

    Employees, students and others have claimed in numerous lawsuits against Monsanto that exposure to PCBs at the Sky Valley center gave them cancer, thyroid conditions and other health problems.

    PCBs are chemicals once widely used to insulate electrical equipment and found in other common products like carbon copy paper, caulking, floor finish and paint. The U.S. government outlawed the chemicals in 1979 after discovering links to cancer.

    The December verdict marked the latest trial loss for Monsanto, which already faced roughly $870 million in verdicts from alleged PCBs exposure at the Sky Valley center in other cases. Monsanto is appealing those verdicts.

    The company has said it stopped producing PCBs in 1977. It has also said the school had been warned repeatedly by government officials that light fixtures containing the chemicals needed to be retrofitted, but that those warnings were ignored.

    The case is Bard v. Pharmacia, King County Superior Court in Washington, No. 21-2-14305-5.

    For the Bard plaintiffs: Henry Jones, Richard Friedman, Sean Gamble and James Hertz of Friedman Rubin

    For Monsanto: Jean-Claude Andre, Elizabeth Blackwell, Kenneth Marshall and Sarah Hartley of Bryan Cave Leighton Paisner

    (Reporting by Clark Mindock)
  9. forum rang 7 4finance 25 april 2024 09:56
    quote:

    LL schreef op 25 april 2024 09:22:

    UPDATE 1-Judge slashes $857 mln Monsanto verdict to $438 mln in PCBs case

    By Clark Mindock

    April 24 (Reuters) - A Washington state judge has nearly halved a $857 million verdict against Bayer’s Monsanto in a lawsuit over chemical pollution at a Seattle-area school, ruling that the company should pay $438 million instead.

    Monsanto spinoff Pharmacia was found liable by a jury in December for selling polychlorinated biphenyls (PCBs) used in the Sky Valley Education Center in Monroe, Washington, that were not safe and did not contain adequate warnings.

    The verdict included $73 million in compensatory damages and $784 million in punitive damages for the plaintiffs, seven former students and parent volunteers at the school who said PCBs caused them neurological, endocrine system and other health issues.

    King County Superior Court Judge Jim Rogers let the $73 million component stand in a ruling on Tuesday, but he reduced punitive damages to five times that amount, or $365 million, and shaved another $1.5 million from the judgment to account for a related settlement.

    Monsanto had argued in January that the original award was unconstitutionally excessive. The U.S. Supreme Court has said that punitive damages should generally not be more than nine times compensatory damages.

    A spokesperson for Monsanto, which agreed to defend Pharmacia in PCBs litigation, said in a statement Wednesday that the company is pleased with the decision but plans to appeal the jury's findings. The spokesperson said the award is still too high and that the plaintiffs were not exposed to unsafe levels of PCBs.

    Spokespeople for the plaintiffs declined to comment on Wednesday.

    Employees, students and others have claimed in numerous lawsuits against Monsanto that exposure to PCBs at the Sky Valley center gave them cancer, thyroid conditions and other health problems.

    PCBs are chemicals once widely used to insulate electrical equipment and found in other common products like carbon copy paper, caulking, floor finish and paint. The U.S. government outlawed the chemicals in 1979 after discovering links to cancer.

    The December verdict marked the latest trial loss for Monsanto, which already faced roughly $870 million in verdicts from alleged PCBs exposure at the Sky Valley center in other cases. Monsanto is appealing those verdicts.

    The company has said it stopped producing PCBs in 1977. It has also said the school had been warned repeatedly by government officials that light fixtures containing the chemicals needed to be retrofitted, but that those warnings were ignored.

    The case is Bard v. Pharmacia, King County Superior Court in Washington, No. 21-2-14305-5.

    For the Bard plaintiffs: Henry Jones, Richard Friedman, Sean Gamble and James Hertz of Friedman Rubin

    For Monsanto: Jean-Claude Andre, Elizabeth Blackwell, Kenneth Marshall and Sarah Hartley of Bryan Cave Leighton Paisner

    (Reporting by Clark Mindock)
    Dat is dus bijna een half miljard voor 1 zaak. Dat wordt een forse rekening als alle zaken zo gaan lopen.
    Dit is een ongekend drama voor Bayer.
  10. forum rang 7 LL 26 april 2024 15:20
    Bayer investor Deka takes a stand against CEO in annual vote
    By Patricia Weiss and Ludwig Burger

    FRANKFURT, April 26 (Reuters) - Bayer shareholder Deka Investment said on Friday it would not join other large investors in supporting the healthcare and agriculture group's management at its annual general meeting.

    Two other larger German mutual fund management houses, DWS and Union Investment, have said they would vote in favour of approving the management board's actions while shareholder advisory firms Glass Lewis and Institutional Shareholder Services (ISS) have recommended such a vote.

    Bayer CEO Bill Anderson will face questions at the AGM over his decision in March to suspend for up to three years any preparations to break apart the German maker of pharmaceuticals, crop protection products and consumer health remedies.

    Anderson, who became CEO in June 2023, has had a tumultuous start with a continued wave of U.S. litigation about an alleged cancer-causing effect of weedkiller glyphosate and a major setback in drug development late last year.

    "We don't regard Mr Anderson's start as successful. We would have wished for more of a focus on aspects that are relevant for the share price," Deka's head of sustainability and corporate governance Ingo Speich said in a speech made available to Reuters ahead of the AGM.

    The vote on ratifying the executive board's business conduct, which prominently wraps up every German AGM, is largely symbolic because it has no bearing on management's liability or tenure. But it is treated as a key gauge of investor sentiment.

    Anderson said in a statement that he would seek to boost drug development, while also tackling litigation, debt and excessive corporate bureaucracy.

    "The soul of this company is alive and well," he said, adding that he would work hard to address shareholders' frustration over the falling share price.

    Harris Associates, another major Bayer shareholder, has told Reuters it strongly supports Anderson, including his decision to suspend work on breaking up the group.

    (Reporting by Ludwig Burger; editing by Friederike Heine and Alexander Smith)
  11. forum rang 7 LL 2 mei 2024 09:04
    Bayer's Monsanto wins reversal of $185 million PCBs verdict in Washington court

    May 1(Reuters) - A Washington state appeals court on Wednesday overturned a $185 million verdict against Bayer's BAYGn.DE Monsanto unit over chemical contamination at a Seattle-area school, marking the second big legal win for the company in as many weeks.

    Monsanto spinoff Pharmacia, which sold now-banned chemicals called polychlorinated biphenyls, was found liable in 2021. Three teachers claimed they suffered brain damage from PCBs that leaked from light fixtures at the Sky Valley Education Center in Monroe, Washington.

    On Wednesday, the state Court of Appeals agreed with Bayer that the lower court improperly applied the laws of Missouri, where Monsanto is based, which allowed the claims to be filed decades after the company stopped producing PCBs in 1977.

    The U.S. government outlawed the chemicals in 1979 after discovering links to cancer.

    Bayer argued Washington law limits liability if exposure occurs outside a product's useful lifespan, which generally means 12 years.

    The case will go back to the lower court to determine whether a new trial is warranted. Plaintiffs' attorney Richard Friedman said in a statement they will retry the case if necessary but hope the state Supreme Court "simply reinstates the verdict" on appeal.

    Bayer faces about 200 similar claims from the school, where people allege PCBs caused cancer, thyroid conditions and other health problems.

    Juries in some of those cases have awarded more than $1.7 billion in compensatory and punitive damages. But another Washington judge nearly halved an $857 million verdict against the company last week in a small group of those claims.

    The company has denied responsibility for the alleged harms and says the school failed to heed repeated warnings to replace the lights. It is appealing the verdicts.

    Monsanto said Wednesday's ruling, which also found the lower court wrongfully allowed punitive damages on some claims and erroneously allowed certain expert testimony, is "significant," and many or all of the other trials from the school may have had the same errors. The company said it will evaluate how to proceed in those cases and others yet to be tried.

    PCBs were once widely used to insulate electrical equipment and found in other common products like caulking and paint.

    (Reporting by Clark Mindock, Editing by Alexia Garamfalvi and Cynthia Osterman)
  12. forum rang 5 Money Never Sleeps 2 mei 2024 09:12
    quote:

    LL schreef op 2 mei 2024 09:04:

    Bayer's Monsanto wins reversal of $185 million PCBs verdict in Washington court

    May 1(Reuters) - A Washington state appeals court on Wednesday overturned a $185 million verdict against Bayer's BAYGn.DE Monsanto unit over chemical contamination at a Seattle-area school, marking the second big legal win for the company in as many weeks.

    Monsanto spinoff Pharmacia, which sold now-banned chemicals called polychlorinated biphenyls, was found liable in 2021. Three teachers claimed they suffered brain damage from PCBs that leaked from light fixtures at the Sky Valley Education Center in Monroe, Washington.

    On Wednesday, the state Court of Appeals agreed with Bayer that the lower court improperly applied the laws of Missouri, where Monsanto is based, which allowed the claims to be filed decades after the company stopped producing PCBs in 1977.

    The U.S. government outlawed the chemicals in 1979 after discovering links to cancer.

    Bayer argued Washington law limits liability if exposure occurs outside a product's useful lifespan, which generally means 12 years.

    The case will go back to the lower court to determine whether a new trial is warranted. Plaintiffs' attorney Richard Friedman said in a statement they will retry the case if necessary but hope the state Supreme Court "simply reinstates the verdict" on appeal.

    Bayer faces about 200 similar claims from the school, where people allege PCBs caused cancer, thyroid conditions and other health problems.

    Juries in some of those cases have awarded more than $1.7 billion in compensatory and punitive damages. But another Washington judge nearly halved an $857 million verdict against the company last week in a small group of those claims.

    The company has denied responsibility for the alleged harms and says the school failed to heed repeated warnings to replace the lights. It is appealing the verdicts.

    Monsanto said Wednesday's ruling, which also found the lower court wrongfully allowed punitive damages on some claims and erroneously allowed certain expert testimony, is "significant," and many or all of the other trials from the school may have had the same errors. The company said it will evaluate how to proceed in those cases and others yet to be tried.

    PCBs were once widely used to insulate electrical equipment and found in other common products like caulking and paint.

    (Reporting by Clark Mindock, Editing by Alexia Garamfalvi and Cynthia Osterman)
    Op 1 mei heeft een beroepsrechtbank in de staat Washington een vonnis van $185 miljoen tegen Bayer’s Monsanto-eenheid teruggedraaid in verband met chemische verontreiniging op een school in de omgeving van Seattle. Dit markeert de tweede grote juridische overwinning voor het bedrijf in evenveel weken.

    De voormalige dochteronderneming van Monsanto, Pharmacia, die nu verboden chemicaliën genaamd polychloorbifenylen (PCB’s) verkocht, werd in 2021 aansprakelijk gesteld. Drie leraren beweerden dat ze hersenschade opliepen door PCB’s die lekten uit verlichtingsarmaturen op de Sky Valley Education Center in Monroe, Washington.

    De rechtbank van beroep in de staat Washington was het eens met Bayer dat de lagere rechtbank de wetten van Missouri, waar Monsanto is gevestigd, onjuist had toegepast. Dit stelde de eisers in staat om decennia na het stoppen van de productie van PCB’s in 1977 hun claims in te dienen.

    De Amerikaanse overheid verbood de chemicaliën in 1979 nadat er verbanden waren ontdekt met kanker.

    Bayer betoogde dat de wet in Washington de aansprakelijkheid beperkt als blootstelling buiten de nuttige levensduur van een product plaatsvindt, wat meestal neerkomt op 12 jaar.

    De zaak wordt terugverwezen naar de lagere rechtbank om te bepalen of een nieuw proces gerechtvaardigd is. De advocaat van de eisers, Richard Friedman, zei in een verklaring dat ze de zaak opnieuw zullen proberen als dat nodig is, maar hopen dat het Hooggerechtshof van de staat het vonnis op beroep “eenvoudigweg herstelt”.

    Bayer wordt geconfronteerd met ongeveer 200 soortgelijke claims van de school, waar mensen beweren dat PCB’s kanker, schildklieraandoeningen en andere gezondheidsproblemen hebben veroorzaakt.

    In sommige van die zaken hebben jury’s meer dan $1,7 miljard aan schadevergoeding en strafschadevergoeding toegekend. Maar een andere rechter in Washington heeft vorige week bij een kleine groep van die claims bijna de helft van een vonnis van $857 miljoen tegen het bedrijf verminderd.Het bedrijf ontkent verantwoordelijkheid voor de vermeende schade en zegt dat de school herhaalde waarschuwingen om de verlichting te vervangen, heeft genegeerd. Bayer gaat in beroep tegen de vonnissen.

    Monsanto zei dat de uitspraak van woensdag ook vaststelde dat de lagere rechtbank ten onrechte strafschadevergoeding had toegestaan
  13. forum rang 10 voda 2 mei 2024 14:19
    Aandeel Bayer flink omhoog na gunstige uitspraak in Monsanto-zaak

    Door ABM Financial News op donderdag 2 mei 2024
    Views: 1.222

    (ABM FN-Dow Jones) De koers van Bayer loopt donderdag 4,4 procent op nadat Monsanto in de VS een tussentijdse juridische overwinning behaalde, waarmee een vonnis ter waarde van 185 miljoen dollar werd ingetrokken.

    Monsanto, dat in 2018 werd overgenomen door Bayer, is al tijden onderwerp van diverse rechtszaken, vanwege gezondheidsrisico's bij het gebruik van de onkruidverdelgers Roundup en Ranger Pro. Het gebruik van de onkruidverdelgers zou mogelijk leiden tot kanker.

    Het Hof van Beroep in de VS verwees de zaak nu terug naar de rechtbank, omdat het twijfelde aan de betrouwbaarheid van de bewijsvoering. Met het eerdere vonnis was 185 miljoen dollar gemoeid.

    Bron: ABM Financial News
304 Posts
Pagina: «« 1 ... 11 12 13 14 15 16 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 913,44 -0,19%
EUR/USD 1,0852 +0,06%
FTSE 100 8.317,59 0,00%
Germany40^ 18.722,80 +0,16%
Gold spot 2.340,36 +0,27%
NY-Nasdaq Composite 16.920,79 +1,10%

Stijgers

Alfen ...
+1,26%
NX FIL...
+1,20%
Accsys
+1,17%
Avantium
+0,92%
Vastned
+0,63%

Dalers

Van La...
-6,40%
B&S Gr...
-1,35%
UMG
-0,87%
PROSUS
-0,79%
Aegon
-0,61%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links